anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Resolution

Beat collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 42,534
Current window 27,241-27,270
Pages 1,418
Rows per page 30
Beat: Resolutionclear collectionreset all
18 30 60

Beat

27,241-27,270 of 42,534

filter-aware
39
The slide displays PK data on both linear and log scales to demonstrate dose-related exposure and half-life characteristics.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
40
The slide compares six different treatment arms across two scales to demonstrate dose-related exposure.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
41
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
42
Clinical trial update slide.Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
43
The slide outlines the methodology for a clinical study, including target sample size (120) and duration (12 months).Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
44
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
45
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
46
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
47
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
48
Anebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slidesAnebulo Pharmaceuticals | Investor Day Presentation Deck | 53 slides · Anebulo Pharmaceuticals
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
03
Comparison of Tmax metrics and safety profiles for single vs repeat dosing.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
04
The slide uses callout boxes connected to specific organs to detail symptom frequency and clinical manifestations.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Agitate (Make it worse)1 hit
05
The chart uses a dual-line comparison to show the divergence in risk outcomes based on treatment timing.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
06
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
07
Includes box plot showing 10th/90th percentiles and line chart showing concentration over 20 minutes.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
08
Box plot showing baseline adjusted epinephrine Tmax.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
09
Shows rapid onset of therapeutic benefits for AQST-109.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
10
Clinical trial data comparing sublingual/oral film (AQST-109) vs intramuscular injection.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
11
The chart shows box plots for baseline adjusted Epinephrine Cmax, highlighting differences in drug exposure between the two treatment groups.Aquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
12
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
13
Aquestive Therapeutics | Results Presentation Deck | 14 slidesAquestive Therapeutics | Results Presentation Deck | 14 slides · Aquestive Therapeutics
Deck Investor relations Beat · Solution (Provide relief)1 hit
09
The slide uses a standard organizational structure layout with headshots and a logo grid for credibility.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
10
The slide uses a horizontal bar chart format to represent clinical trial stages for different drug combinations.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
11
The pie chart visualizes the relative size of the patient populations described in the list.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
30
The slide uses a combination of scientific evidence (left) and market/trial status (right) to justify investment.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
31
The slide uses a matrix layout to map drug assets against biological targets and development status (marketed, late-stage, early-stage, preclinical).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
32
The slide uses a high-emotion photo of a father and son to humanize the medical topic.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
33
The slide uses a matrix-like layout to map drug assets against therapeutic areas and development status.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
34
Includes a visual representation of the metabolic pathway and radiographic evidence of treatment efficacy.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
35
The slide uses a Venn-style diagram to illustrate market expansion.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Impact & Next Steps1 hit